Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Sunrest Lifescience Ltd (SUNREST)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: SUNREST Trading | Small Cap | Sunrest Lifescience Share Price
BSE Share Price
Not Listed
Not Listed
Sunrest Lifescience Ltd (SUNREST)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: SUNREST Trading | Small Cap | Sunrest Lifescience Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹32 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹4.8
TTM Sales
₹70.8 Cr.
Book Value per Share
₹28.8
P/E Ratio
7.76
Lower than its 5-year historical median
Industry PE
40.5
Price to Book (P/B)
1.29
Lower than its 5-year historical median
Price to Sales (P/S)
0.45
Lower than its 5-year historical median
EV/EBITDA
3.67
Lower than its 5-year historical median
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
43.52%
Outperforms industry median
Return on Capital Employed (ROCE)
34.78%
Outperforms industry median
Return on Assets (ROA)
12.37%
Operating Profit Margin
14.4%
Net Profit Margin
11.29%
Gross Profit Margin
16%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
0.42%
Operating Profit Growth (1 Year)
-
238.08%
Net Profit Growth (1 Year)
-
297.51%
Asset Quality
Promoter Holding
53.50%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹16 Cr.
Equity
₹8.6 Cr.
Face Value
₹10
All Time Low / High
₹0.00 / 0.00
Check Before You Invest
M-Cap below 100cr DeciZen not available
Is Sunrest Lifescience Ltd a good quality company?
Sunrest Lifescience Ltd is a quality company, based on a multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Sunrest Lifescience Ltd performance compare with that of its Peers?
Revenue growth of Sunrest Lifescience Ltd vs industry peers?
Sunrest Lifescience Ltd revenue CAGR is 14.43%, compared to the industry median CAGR of 0.9%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Sunrest Lifescience Ltd?
Promoters hold 53.50% of the Sunrest Lifescience Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Sunrest Lifescience Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -19.65% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sunrest Lifescience Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 5.7% | 9.3% | 31% | 58.6% | 6.3% | 13.6% | 18.1% | - |
| Value Creation Index ⓘ | -0.6 | -0.3 | 1.2 | 3.2 | -0.6 | 0.0 | 0.3 | - |
Growth Parameters ⓘ |
||||||||
| Sales ⓘ | 11 | 17 | 26.9 | 24.6 | 29.5 | 33.1 | 33.3 | 33 |
| Sales YoY Gr. | - | 54.8% | 58.6% | -8.4% | 19.6% | 12.4% | 0.4% | - |
| Adj EPS ⓘ | 0.1 | 0.6 | 2.5 | 6.8 | 0.5 | 4.7 | 7.2 | 3.6 |
| YoY Gr. | - | 358.3% | 361.8% | 168.1% | -92.2% | 779.3% | 54.5% | - |
| BVPS (₹) ⓘ | 0.4 | 1 | 3.6 | 10.4 | 33.1 | 37.7 | 44.9 | 27.5 |
| Adj Net Profit ⓘ | 0 | 0.2 | 0.8 | 2 | 0.2 | 2 | 3.1 | 3 |
| Cash Flow from Ops. ⓘ | -0.9 | 0.2 | -0.5 | 1.2 | -14.8 | 1.4 | -0.7 | - |
| Debt/CF from Ops. ⓘ | -2.5 | 15.1 | -7.2 | 1.9 | -0.4 | 4.3 | -13.5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 14.4% | 10.5% | 0.4% | ||||
| Adj EPS ⓘ | NA | 67.3% | 1.9% | 54.5% | ||||
| BVPSⓘ | NA | 114.9% | 63% | 19.1% | ||||
| Share Price | - | - | - | -24.2% | ||||
Key Financial Parameters ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 28.4 | 78 | 111.4 | 97.6 | 2.6 | 13.2 | 17.4 | 10 |
| Op. Profit Mgn % ⓘ | 1.4 | 1.6 | 4.1 | 11.8 | 3.1 | 9.1 | 14.5 | NAN |
| Net Profit Mgn % ⓘ | 0.3 | 1 | 2.8 | 8.3 | 0.8 | 6 | 9.3 | 9.3 |
| Debt to Equity ⓘ | 17.5 | 7.9 | 3 | 0.7 | 0.4 | 0.4 | 0.5 | - |
| Working Cap Days ⓘ | 0 | 160 | 143 | 207 | 250 | 290 | 333 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 54 | 30 | 55 | 128 | 153 | 164 | 0 |
Valuation of Sunrest Lifescience - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Sales | 33.41 | 70.83 |
| Operating Expenses ⓘ + | 30.39 | 60.63 |
| Operating Profit ⓘ | 3.02 | 10.21 |
| Operating Profit Margin (%) | 9.0% | 14.4% |
| Other Income ⓘ + | 0 | 2.51 |
| Interest ⓘ | 0.31 | 1.42 |
| Depreciation ⓘ | 0.10 | 1.19 |
| Profit Before Tax ⓘ | 2.62 | 10.10 |
| Tax ⓘ | 0.61 | 2.11 |
| Profit After Tax | 2.01 | 7.99 |
| PAT Margin (%) | 6.0% | 11.3% |
| Adjusted EPS (₹) | 4.7 | 9.6 |
| Dividend Payout Ratio (%) | 0% | 0% |
| PARTICULARS | Mar'25 | Mar'26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 16.31 | 20.43 | |||||||||
| Debt + | 11.98 | 16.97 | |||||||||
| Minority Interest | 5.32 | 9.2 | |||||||||
| Trade Payables | 22.93 | 21.02 | |||||||||
| Others Liabilities ⓘ | 1.70 | 3.44 | |||||||||
| Total Liabilities ⓘ | 58.24 | 71.05 | |||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 4.36 | 8.55 | |||||||||
| CWIP ⓘ | 0 | 0 | |||||||||
| Investments ⓘ | 0 | 0 | |||||||||
| Inventories | 9.62 | 17.06 | |||||||||
| Trade Receivables | 36.37 | 32.46 | |||||||||
| Cash Equivalents | 1.74 | 2.76 | |||||||||
| Others Assets ⓘ | 6.15 | 10.21 | |||||||||
| Total Assets ⓘ | 58.24 | 71.05 | |||||||||
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 2.92 | -0.05 |
| Cash Flow From Investing Activity ⓘ + | -1.15 | -2.91 |
| Cash Flow From Financing Activity ⓘ + | -0.33 | 3.99 |
| Net Cash Flow ⓘ | 1.45 | 1.03 |
| PARTICULARS | Mar'25 | Mar'26 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 12.33 | 43.52 | ||||||||
| ROCE (%) | 10.33 | 34.78 | ||||||||
| Asset Turnover Ratio | 0.57 | 1.1 | ||||||||
| PAT to CFO Conversion(x) | 1.45 | -0.01 | ||||||||
| Working Capital Days | ||||||||||
| Receivable Days | 397.30 | 177.30 | ||||||||
| Inventory Days | 105.10 | 68.80 | ||||||||
| Payable Days | 417.10 | 181.30 | ||||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Sunrest Lifescience Ltd FAQs
The current trading price of Sunrest Lifescience on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Sunrest Lifescience stood at ₹31.93 Cr
The latest P/E ratio of Sunrest Lifescience as of 31-Dec-1969 is 10.34.
The latest P/B ratio of Sunrest Lifescience as of 31-Dec-1969 is 1.35.
The 52-week high of Sunrest Lifescience is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sunrest Lifescience is ₹33.26 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Sunrest Lifescience Ltd is a below average quality company.
The key valuation ratios of Sunrest Lifescience Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sunrest Lifescience Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Sunrest Lifescience Ltd
Sunrest Lifescience was originally incorporated as ‘Sunrest Lifescience Private Limited’ as a Private Limited Company under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated October 30, 2017, issued by the Registrar of Companies, Ahmedabad, Gujarat. Subsequently, the company was converted into a Public Limited Company pursuant to shareholders resolution passed at Extra-ordinary General Meeting of the company held on March 09, 2023 and the name of the company was changed to ‘Sunrest Lifescience Limited’. A fresh Certificate of Incorporation consequent upon Conversion from Private Limited Company to Public Limited Company was issued by the Registrar of Companies, Ahmedabad on March 21, 2023.
The company is engaged in the marketing of OTC generic pharmaceutical products in the domestic market. The company offer range of pharmaceutical products manufactured by third party manufacturers. The company operates in different States of India such as Maharashtra, Gujarat, Madhya Pradesh, Orissa and Rajasthan. The company have presence in these States through Trade Mark registered products and/or products under registration. It deals in Capsules, Tablets, Syrup, Ointment, Gel, Mouth Wash, Solution, Suspension, Dry Powders and Toothpaste.
Its product portfolio comprises of vide range of drugs like Anti-Bacterial, Anti Diarrheal, AntiFungal, Anti Malerial, Anti Diabetic, Dental Cure, Anti Protozol, Anti Histamine, Anti-Hypertensive drugs, Cosmetic, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical and Anti-inflammatory. The company has 18 Registered Trademarks for 32 products. The products of the Company are sold to Stockists and Super Stockists & in turn it is available at Chemist shops, Dispensaries, Hospitals etc. Its business operations are supported by one of its Group Company and various third-party manufacturers. It typically works on third-party manufacturing basis or at times purchase order basis with manufacturer of pharma products, depending upon customer’s requirement.
Business area of the company
The company is engaged in the business of marketing and distribution of pharmaceutical products in the domestic market. The company offers wide range of pharmaceutical formulations and products manufactured by third party manufacturers.
Products of the company
- Capsule
- Drop
- Facewash
- Gel
- Mouth Wash
- Ointment
- Toothpest
- Syrup
- Tablet
You have 46 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
